Fintel reports that on March 28, 2025, Stifel downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from Buy to ...

Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives process underway to maximize value creation across ...

SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today ...

Stifel downgraded Third Harmonic Bio (THRD) to Hold from Buy with a price target of $5, down from $23, following the company’s decision to ...

Corporate Strategic Outlook In parallel with THB335 Phase 2 readiness activities, Third Harmonic Bio has initiated a process to identify opportunities to maximize shareholder value through a ...

This compares with $30.82 million, or $0.78 per share, last year. Third Harmonic Bio, Inc. earnings at a glance (GAAP) : -Earnings: $45.47 Mln. vs. $30.82 Mln. last year. -EPS: $1.09 vs.